On Tuesday, BMO Capital Markets revised its price target for Neurogene (NASDAQ:NGNE), a biotechnology firm, decreasing it to $45 from the previous $60. The firm maintained its Outperform rating on the company's shares despite the adjustment. The revision follows a series of developments that have impacted Neurogene's stock performance, including concerns over patient safety in clinical trials.
Neurogene's shares have been trading close to the company's cash value, influenced by an emerging serious adverse event (SAE) in a patient receiving a high dose of treatment. This SAE is consistent with symptoms of overexposure or overdose of AAV9, an adeno-associated virus used in gene therapy, similar to issues seen with another gene therapy product, Zolgensma. Despite this, phase 1/2 data for Neurogene's low-dose treatment remains promising.
The company's decision to terminate its Batten's disease program, which was publicly announced on November 11, has also played a role in the reassessment of the stock's potential. Investors are currently cautious, anticipating the possible tragic outcome for the patient who experienced the high-dose SAE, as noted in medical literature.
Neurogene's management has been in discussions with the Food and Drug Administration (FDA) and does not anticipate a clinical hold, acknowledging the safety profile of the low-dose treatment. Looking forward, the company expects to provide a registrational update in the first half of 2025 and a readout for the low-dose treatment in the second half of the same year, which are anticipated to be the next significant catalysts for the stock.
In other recent news, Neurogene has reported promising earnings and revenue results, with a Q2 2024 net loss of $18.5 million and R&D expenses of $15.7 million. The company secured approximately $200 million in oversubscribed PIPE financing, expected to extend its financial runway into the second half of 2027. These funds will support the completion of enrollment for the study of NGN-401, Neurogene's investigational therapy for Rett syndrome.
The company's clinical program for NGN-401 has seen recent developments. A systemic hyperinflammatory syndrome, a serious adverse event (SAE), was identified in a patient who received a high dose of NGN-401, leading to the termination of the high-dose cohort of the study. However, Neurogene plans to continue enrolling patients at a lower dose of 1E15 vg, with enrollment expected to be completed in 2025.
Analysts from BMO Capital, Stifel, Baird, and H.C. Wainwright have adjusted their price targets for Neurogene. Notably, BMO Capital reduced its price target to $60 from $65, while Stifel increased its price target to $60 from $44. Baird lifted its price target to $72 from $54, and H.C. Wainwright raised its price target to $55 from $49.
NGN-401 has demonstrated efficacy and safety at the lower dose in a small cohort of patients. However, the therapy's high dose was associated with a treatment-related adverse event. The design of registrational endpoints and pivotal trials for NGN-401 is yet to be determined, with updates expected in the first half of 2025.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Neurogene's financial situation and market performance, providing context to the BMO Capital Markets' revised price target. The company's market capitalization stands at $225.57 million, reflecting the recent stock price movements.
InvestingPro Tips highlight that Neurogene holds more cash than debt on its balance sheet, which could provide some financial stability during this challenging period. However, the company is also quickly burning through cash, a common characteristic of biotechnology firms in the development stage.
The stock's recent performance has been notably volatile, with InvestingPro data showing a significant 50.45% drop in the past week and a 63.57% decline over the last month. This aligns with the article's mention of investor caution following the serious adverse event in clinical trials.
Despite these challenges, analysts maintain a fair value target of $60 for Neurogene, suggesting potential upside from current levels if the company can navigate its current hurdles successfully.
For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips for Neurogene, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.